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Abstract
Background: Cyclical Vomiting Syndrome (CVS) is characterised by discrete, unexplained
episodes of intense nausea and vomiting, and mainly affects children and adolescents.
Comprehending Cyclical Vomiting Syndrome requires awareness of the severity of nausea
experienced by patients. As a subjective symptom, nausea is easily overlooked, yet is the most
distressing symptom for patients and causes many behavioural changes during attacks.
Case presentation: This first-hand account of one patient's experience of Cyclical Vomiting
Syndrome shows how severe nausea contributed to the development of anticipatory nausea and
vomiting (ANV), a conditioned response frequently observed in chemotherapy patients. This
conditioning apparently worsened the course of the patient's disease. Anticipatory nausea and
vomiting has not previously been recognised in Cyclical Vomiting Syndrome, however predictors
of its occurrence in oncology patients indicate that it could complicate many cases.
Conclusion: We suggest a model whereby untreated severe and prolonged nausea provokes
anxiety about further cyclical vomiting attacks. This anxiety facilitates conditioning, thus increasing
the range of triggers in a self-perpetuating manner. Effective management of the nausea-anxiety
feedback loop can reduce the likelihood of anticipatory nausea and vomiting developing in other
patients.
Background
Cyclical Vomiting Syndrome (CVS) has been recognised
for over 100 years [1]. It is probably a manifestation of
migraine diathesis [2], and is characterised by recurrent
episodes of intense [3,4] nausea and vomiting, with nor-
mal health between emetic crises. Attacks are self-limiting,
lasting several hours to over a week, and their duration is
often stereotypical for each patient [5]. Episodes of CVS
are most commonly precipitated by infections, physical or
emotional stress, excitement, or specific foods [6], and
often commence during the night or early morning [3,6].
The following case report is that of the first author. It is
derived from patient memory and family diaries, and
describes a previously unrecognised complication of CVS
that is invisible to the clinician due to its subjectivity. It
suggests a triggering mechanism based upon classical con-
ditioning and exacerbated by anxiety about the prospect
of severe nausea, similar to the anticipatory nausea and
vomiting (ANV) seen in chemotherapy patients. Recogni-
tion and effective management of nausea can reduce the
risk of this complication from developing in other CVS
patients.
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A 28-year-old postdoctoral researcher experienced multi-
ple episodes of vomiting from the age of 3 years. The epi-
sodes occurred with upper respiratory tract infections and
asthma, and generally lasted 24–48 hours. The patient's
mother had nearly identical episodes during childhood.
The maternal grandmother experienced hyperemesis
gravidarum. The patient's sister and paternal grandfather
had classical migraine headaches.
The patient first presented to the hospital at age 10 1/2
years. A typical vomiting attack had been triggered by a
cold, but had not resolved after four days. Despite treat-
ment with intravenous fluids, the vomiting continued for
a further two days before resolving. Cyclical vomiting was
diagnosed. She was subsequently hospitalised repeatedly
with episodes of about four days duration, with vomiting
occurring every 5 to 10 minutes at peak. She continued to
have similar attacks during every infection, but never with-
out prior infection. The symptoms were refractory to anti-
emetics available at the time (eg. metoclopramide,
prochlorperazine).
Shortly before Christmas of that year (1986), a 6 1/2-day
vomiting episode was triggered by pneumonia, and the
patient spent the Christmas period in hospital. The fol-
lowing year (1987), a cold triggered a CVS attack two days
before Christmas. Having spent two successive Christ-
mases in hospital, the patient hoped to be well the next
year. However, she was woken by nausea in the early
hours of Christmas Day 1988 and began vomiting.
Uniquely, this episode had not been triggered by an infec-
tion, and the patient (then aged thirteen) recognised this.
Subsequently, episodes rapidly increased in frequency:
compared with an average of 7.3 episodes per year in the
three preceding years, the patient averaged 22.3 episodes
per year over the three years following Christmas 1988.
Many further episodes now occurred without infection,
but coincided with visits to certain places (e.g. friend's
house), or commenced on specific days of the week (e.g.
Saturday). Most episodes resulted in 3–8 day hospitalisa-
tions. At one point, a repetitive cycle commenced, where
each episode occurred exactly two days after discharge
from hospital following the previous attack. The patient
was aware of this pattern and consciously afraid of becom-
ing ill at the expected time. Her attacks always com-
menced nocturnally and she became reluctant to go to
sleep, fearful of another episode beginning.
The patient experienced exhaustion and severe, intracta-
ble nausea for the entire length of her emetic episodes (up
to 6 1/2 days), and the nausea caused marked behavioural
changes. Sleep was the only state that allowed her to be
insensible to nausea, but she was often unable to lie
down, as this intensified her nausea, causing retching and
heartburn. Instead, she spent hours sitting motionless in
bed with her hips and knees flexed, her arms and head
resting on her knees and her eyes closed. She was unable
to lie supine for abdominal palpation. She would repeat-
edly expectorate, as she experienced hypersalivation [7]
and was too nauseated to swallow. Accumulated oral
secretions, and the profound fatigue and confusion that
accompany nausea, contributed to her verbal unrespon-
siveness. Attempting to reduce intolerable nausea, she fre-
quently induced vomiting by drinking large volumes of
water. This also diluted bile and gastric acid, thus lessen-
ing oesophageal and oropharyngeal discomfort during
vomiting [7].
Consistent with the natural history of the condition, the
attacks gradually became less frequent as the patient grew
older. Availability of newer anti-emetic agents (5-HT3
antagonists) also contributed to the improvement:
prompt treatment of episodes with intravenous ondanset-
ron, ranitidine and analgesics reduced the duration and
severity of attacks, and the same medications were par-
tially successful as prophylactics. Thus, having achieved
partial symptom control, and an understanding of how
her anticipation of episodes was exacerbating her condi-
tion (and therefore when to use prophylactic medication),
the patient felt more in control of her illness, feared it less,
and conditioned responses to situations previously asso-
ciated with CVS attacks gradually diminished. To date, the
patient has been hospitalised nearly 100 times, however
now experiences vomiting attacks only rarely (fifteen epi-
sodes over the past decade, including only one episode
over the past five years).
Discussion
The emetic reflex has evolved to expel ingested toxins [4].
Nausea is a vital component of this protective reflex: as an
intensely unpleasant sensation it subsequently causes
potent aversion to the offending food through associa-
tion. Thus a key feature of nausea is its rapid conditioning,
and non-vomiting species (e.g. rodents) rely solely upon
this 'conditioned taste-aversion' for avoiding toxins.
Unfortunately, this evolutionary legacy is problematic in
clinical situations. Oncology patients whose vomiting is
caused by cytotoxic drugs may also develop emesis prior to
subsequent treatments [8]. This anticipatory nausea and
vomiting (ANV) occurs through classical (Pavlovian) con-
ditioning [8,9]. Chemotherapy (the unconditioned stim-
ulus) is administered in hospital (the conditioned
stimulus). Chemotherapy causes emesis (the uncondi-
tioned response). Patients subsequently associate the hos-
pital with nausea and vomiting: smells, sights, or thoughts
of the hospital can then elicit emesis (the conditioned
response) without the emetogenic agent.Page 2 of 4
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involved in pregnancy-sickness [11]. However, its occur-
rence in CVS has remained unrecognised. In this patient's
case, ANV increasingly precipitated CVS episodes. Before
Christmas 1988, attacks only occurred during infections.
Christmas (associated with infection and vomiting in two
successive years) was the first conditioned stimulus.
Christmas subsequently elicited the conditioned response
(vomiting) in the absence of the unconditioned stimulus
(infection). Occurrence of attacks without prior infection
caused the patient to fear the illness and search for alter-
native triggers. A concurrent increase in the frequency of
episodes occurred, and increasingly insignificant events
associated with past episodes became sufficient to trigger
vomiting. This 'stimulus generalisation', whereby condi-
tioned stimuli become progressively less specific, is a fea-
ture of conditioned responses [9]: in some oncology
patients the sight of any nurse can eventually induce eme-
sis [9]. In our CVS patient, fear or expectation of an attack
in itself became a trigger, and she became conscious of
this. Consequently, many attacks occurred before impor-
tant occasions (e.g. holidays, family celebrations, school
examinations, university interviews), when she particu-
larly wished to remain well: this constantly reinforced
conditioning. As her episodes always commenced during
sleep, she felt powerless to control her ANV.
One study [12] found ANV in 59% of paediatric cancer
patients. Development of ANV is positively correlated
with severity of vomiting (intensity, frequency, duration)
and number of chemotherapy cycles ('conditioning tri-
als'); and inversely with patient age [9,13]. In CVS, the
severity of emesis [4] and number of conditioning trials
can exceed that in chemotherapy patients, and CVS
mainly affects children. Based on these predictors, and the
intrinsic evolutionary links between conditioning and
nausea, other CVS patients might develop ANV, as illus-
trated by another young woman's description: " [For]
about two months...I would get sick every Saturday morn-
ing. I would be sick until Wednesday, feel good on Thurs-
day and Friday and then the cycle would start all over.
Looking back at it now, I know I worried when next Satur-
day would roll around. I think I worried myself so much
that in a way I helped my body into the cycle." [14]. We
believe that ANV could complicate many CVS cases in
addition to these two, but is extremely difficult for clini-
cians to recognise. Whilst triggers for chemotherapy-asso-
ciated ANV are specific, controlled, and can be objectively
observed by doctors within the hospital; the conditioned
stimuli for CVS-associated ANV are subtle (e.g. certain day
of the week), subjective (e.g. fear of a CVS attack), and
occur outside of the hospital, thus are invisible to doctors.
As a first-hand account, this case report therefore provides
a unique, qualitative perspective on triggering factors as
viewed through the eye of the patient, and reveals the hid-
den role of conditioning.
ANV progressed in this patient because of her extremely
severe nausea, and her consequent fear of future episodes.
Conditioning is more potent when the patient is anxious
[13,15,16]; and in patients who expect and experience
much distress from nausea [12]. Based on these observa-
tions, therapy to prevent ANV in CVS should have two
aims: reduction of nausea, and reduction of anxiety. Con-
sistent with this, it is noted that CVS patients who are
given prompt anti-nausea treatment during an attack
experience recurrence of attacks less frequently [7].
Unfortunately, most CVS patients are treated by non-spe-
cialists, who may overlook nausea as it is subjective and
unquantifiable [17,18]. Standard management therefore
focuses on rehydration, which, without controlling nau-
sea, cannot prevent dread of future attacks and the devel-
opment of ANV. Iatrogenic anxiety may exacerbate this:
nausea-induced behavioural changes seen during attacks
[2,7], which may appear 'psychotic' [19] and 'regressive'
[20], can prompt the misdiagnosis of factitious vomiting
[2], hence raising patient anxiety through stigmatisation.
For example, the patient reported here feared being ill
before school examinations not only because of the phys-
ical unpleasantness of the illness and the educational con-
sequences of missing important exams, but also because
she believed that her doctors would interpret a CVS attack
at such a time as evidence of psychosomatic illness.
Management of nausea should comprise an individual-
ised plan devised between patient and physician. Where
attacks are sufficiently frequent to justify daily medica-
tion, anti-migraine prophylaxis (e.g. cyproheptadine, piz-
otifen, amitriptyline or propranolol) might help prevent
episodes. Prophylaxis also requires amelioration of
known triggering factors, e.g. acute or chronic infection.
In patients with prodromal symptoms, oral ondansetron
and/or lorazepam sometimes abort the episode. If vomit-
ing commences, an intravenous infusion containing glu-
cose, sodium, potassium and ranitidine should be started
immediately. Intravenous ondansetron and lorazepam
may terminate vomiting; otherwise the patient should be
sedated to reduce sensations of nausea. This can be
achieved using intravenous chlorpromazine plus diphen-
hydramine every 3 to 4 hours until the episode abates.
The second goal of therapy, reduction of anxiety about the
illness, will result from successful treatment of nausea, but
is also facilitated by a patient-centred, holistic approach to
care. Established ANV can be treated by relaxation-based
behavioural approaches such as 'counterconditioning'
(systematic desensitisation) and hypnosis [11]. However,
as ANV is mediated through the normal psychologicalPage 3 of 4
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process of classical conditioning, it should be regarded as
a normal response to severe nausea, and not as a primary
anxiety disorder (although pre-existing anxiety could
exacerbate ANV). Oncology patients often assume that
ANV is indicative of something psychologically wrong
with them (which causes further anxiety), and are there-
fore reluctant to report it to hospital staff [21], so reassur-
ance of its normality is important.
Conclusion
This report illustrates the potential importance of ANV as
a self-perpetuating triggering mechanism in CVS, and
describes the positive feedback loop between nausea and
anxiety. Conditioning might contribute to regular timing
of episodes in some patients [2], account for seemingly
implausible triggers, and explain attacks that superficially
appear to be triggered by excitement or stress (e.g. Christ-
mas, exams). Its prevalence in other CVS patients should
therefore be investigated. Correct management of CVS
should help to prevent ANV, and to reverse it where it has
already arisen.
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